https://www.selleckchem.com/products/rbn-2397.html
cial support, disclosing their HIV status, and getting early treatment for any opportunistic infection is crucial to patients. Eculizumab, a drug that blocks activation of the terminal complement pathway, is useful in the treatment of several rare diseases. However, eculizumab-related meningococcal disease is a serious problem. Because of the difficulty diagnosing meningococcal disease, deaths from meningococcal disease may have been overlooked. The purpose of this study was to clarify the trend of meningococcal infection in patients o
Like
Comment
Share
